ReviewNature reviews. Urology2020
Expanding the role of small-molecule PSMA ligands beyond PET staging of prostate cancer.
Review in Nature reviews. Urology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 26 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
26 citing papers in PubMed, 57 citations in OpenAlex.
- Quantitative dual-tracer PET/CT biomarkers correlate concordant lesion uptake with PSMA-RLT outcomes in mCRPC: a dual-center study.European journal of nuclear medicine and molecular imaging · 2026Article
- Active-targeting biomimetic nanosystem for prostate cancer enhances radiotherapy efficacy by inducing ferroptosis.Journal of nanobiotechnology · 2025Article
- Managing incidental findings in total body PET/CT studies: balancing ethical considerations and resource constraints.EJNMMI reports · 2025Article
- Emerging innovative treatment strategies for advanced clear cell renal cell carcinoma.The oncologist · 2025Review
- Novel radiopharmaceuticals for molecular imaging of renal cell carcinoma.BMJ oncology · 2025Review
- Genetic implications of PSMA expression variability in breast cancer subtypes with a focus on triple-negative breast cancer.Journal of applied genetics · 2024Article
- The Imageable Genome.Nature communications · 2023Article
- Current Status of Radiolabeled Monoclonal Antibodies Targeting PSMA for Imaging and Therapy.Cancers · 2023Review
- Future of prostate imaging: Artificial intelligence in assessing prostatic magnetic resonance imaging.World journal of radiology · 2023Review
- Intense PSMA Uptake in a Vertebral Hemangioma Mimicking a Solitary Bone Metastasis in the Primary Staging of Prostate Cancer viaDiagnostics (Basel, Switzerland) · 2023Article
- Feasibility of biology-guided radiotherapy for metastatic renal cell carcinoma driven by PSMA PET imaging.Clinical and translational radiation oncology · 2023Article
- A Dimeric FAP-Targeting Small-Molecule Radioconjugate with High and Prolonged Tumor Uptake.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- PSMA Expression in Solid Tumors beyond the Prostate Gland: Ready for Theranostic Applications?Journal of clinical medicine · 2022Review
- Hetero-bivalent agents targeting FAP and PSMA.European journal of nuclear medicine and molecular imaging · 2022Article
- Emerging Targets in Clear Cell Renal Cell Carcinoma.Cancers · 2022Review
- Impact of Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography in the Management of Oligometastatic Renal Cell Carcinoma.European urology open science · 2022Article
- The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer.Nature reviews. Urology · 2022Review
- Role of PSMA-ligands imaging in Renal Cell Carcinoma management: current status and future perspectives.Journal of cancer research and clinical oncology · 2022Review
- Comparison ofEJNMMI research · 2022Article
- Identification of alternative protein targets of glutamate-ureido-lysine associated with PSMA tracer uptake in prostate cancer cells.Proceedings of the National Academy of Sciences of the United States of America · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Prostate-specific membrane antigen (PSMA) positron emission tomography (PET) is rapidly being established as arguably the leading contemporary imaging modality in the management of prostate cancer. Outside of its conventional use in the de novo staging of localized disease and detection of biochemical recurrence, additional applications for the use of PSMA PET are emerging. Uptake of PSMA tracers in other genitourinary malignancies, particularly renal cell carcinoma, has led to new fields of investigation. Therapeutic delivery of radiolabelled PSMA small molecules has shown considerable promise in advanced prostate cancer. The ability to use the same molecule for imaging and therapy - theranostics - enables a highly personalized approach. PSMA PET can also have a considerable influence in the selection and guidance of radiotherapy fields for high-risk and recurrent disease. Intriguingly, changes in intensity of PSMA uptake during systemic therapy might provide early response assessment or novel insight into the biological responses of genitourinary malignancies to treatment. An evolving range of radiolabelled PSMA radiopharmaceuticals is emerging in the multiple facets of modern clinical practice.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.